Biofilm Antibiotic Tolerance: Targeting Physical Barriers and Bacterial Signaling Networks
Background: Resistance is not the only reason antibiotics fail
Bacterial survival during antibiotic exposure in biofilms reflects the combined effects of structures that limit drug penetration, bacterial metabolic state, and signaling regulation. A review in the international journal Virulence summarizes these defense mechanisms and examines the potential and limitations of treatment strategies targeting structural disruption, signaling control, and drug delivery. It does not report new experimental or clinical trial results.
Biofilms consist of microbial communities and the extracellular polymeric substances (EPS) they secrete. A matrix of interwoven polysaccharides, proteins, and extracellular DNA helps bacteria attach and maintain communities. Biofilms on medical device surfaces or at sites of chronic infection can allow bacteria to survive treatment and contribute to recurrent infection.
Antibiotic resistance and tolerance are distinct. Resistance is the ability of bacteria to grow even at high drug concentrations, for example as a result of genetic changes, and is reflected in an increased minimum inhibitory concentration (MIC). Tolerance is the ability to withstand antibiotic exposure for a period without a change in MIC. Persistence—the survival of a subset of the population known as persister cells—is also distinct from genetic resistance. Persister cells cannot all be described as having completely stopped metabolizing.
Key findings: Matrix, metabolism, and signaling regulation form an interconnected defense
The defenses summarized in the review go beyond simple physical blocking. EPS can adsorb drugs or slow their diffusion into the biofilm, changing local drug distribution. Uneven oxygen and nutrient availability can lower bacterial metabolism and reduce the activity of physiological processes targeted by some antibiotics. The effect varies by drug. Low-oxygen conditions do not reduce the efficacy of all antibiotics uniformly.
Horizontal gene transfer contributes to the spread of genetic resistance. Dense bacterial populations and DNA retained in the matrix provide a basis for genetic exchange. However, the matrix can also limit cell-to-cell contact under some conditions, so it is difficult to conclude that biofilms always promote every route of gene transfer.
Quorum sensing (QS) and the bacterial second messenger c-di-GMP regulate attachment, matrix production, and dispersal. Interactions between these systems vary with bacterial species, developmental stage, and environment. Simultaneously inhibiting both signals should not be interpreted as a universal solution that always improves treatment efficacy.
Intervention strategies also differ by their points of action. The review describes the recombinant enzyme rSpdAZ, which degrades extracellular DNA; echinacoside, which lowers c-di-GMP levels in Pseudomonas aeruginosa and enhances tobramycin activity; and drug delivery vehicles, among other examples. As an example of gene editing, it cites targeting ptsH, a gene associated with persister formation in Klebsiella pneumoniae. These are examples from separate cited studies, not results validated in a single combination-therapy experiment.
Significance and outlook: The rationale for combination strategies and the gap in clinical validation
The review connects multiple mechanisms involved in antibiotic treatment failure with intervention targets. Matrix degradation dismantles existing barriers, while signaling control alters formation, maturation, and dispersal. Delivery vehicles aim to improve drug distribution, and persister targeting addresses the physiological state and related pathways of cells that survive. Other pathways in regulatory networks may compensate, which can limit interventions aimed at a single target.
Most strategies, however, remain at the proof-of-concept or animal-testing stage. Challenges include the long-term toxicity and clearance of nanomaterials, delivery efficiency and off-target effects of gene editing, and stability in complex infection environments. The researchers propose multi-omics analyses and models that better represent human infection environments as future directions. Additional clinical evidence is needed to connect the proposed mechanisms to reduced infections or successful treatment in patients.
Sources are the provided excerpt from the Virulence review and Europe PMC bibliographic record and abstract.
The stable structure of biofilms and the characteristics of the bacteria within them make biofilms an important barrier for bacteria to resist external stress, and a key factor contributing to the difficulty of eradicating clinical infections. This article reviews the multi-stage formation process of biofilms, the various mechanisms of antibiotic tolerance and resistance (such as physical barriers, metabolic adaptations, horizontal gene transfer, etc.), as well as the integrated regulatory roles of molecular networks like quorum sensing (QS) and cyclic diguanosine monophosphate (c-di-GMP). These multiple protective mechanisms in biofilms compose a closed "structure-function" loop system. In the past few years, the emergence of new anti-biofilm intervention approaches (matrix-degrading enzymes, phage therapy, nanomaterials, gene editing, etc.) revealed the possibility to break the limitations of conventional antibiotics by compromising structural integrity or interfering with signaling pathways, providing new ideas for drug-resistance infection control.
If this review’s framework were applied to development research modeling catheter-related infection, one possible scenario would assess separately whether biofilm quantity decreases and whether living bacteria are eliminated. Disrupting the structure and killing bacteria in a tolerant state require different assessments. The framework could also help distinguish which defense mechanism each strategy targets when comparing matrix-degrading agents, signaling modulators, and antibiotic delivery vehicles. Such an approach would examine drug penetration, bacterial survival, and regrowth together and assess differences associated with bacterial species, matrix composition, and infection environment. This is an example of how the review could inform research design. It is not yet a basis for recommending a specific combination therapy to patients or predicting a reduction in infection rates.